[HTML][HTML] Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs

ELC Tan, EE Ooi, CY Lin, HC Tan, AE Ling… - Emerging infectious …, 2004 - ncbi.nlm.nih.gov
ELC Tan, EE Ooi, CY Lin, HC Tan, AE Ling, B Lim, LW Stanton
Emerging infectious diseases, 2004ncbi.nlm.nih.gov
Severe acute respiratory syndrome (SARS) is an infectious disease caused by a newly
identified human coronavirus (SARS-CoV). Currently, no effective drug exists to treat SARS-
CoV infection. In this study, we investigated whether a panel of commercially available
antiviral drugs exhibit in vitro anti–SARS-CoV activity. A drug-screening assay that scores for
virus-induced cytopathic effects on cultured cells was used. Tested were 19 clinically
approved compounds from several major antiviral pharmacologic classes: nucleoside …
Abstract
Severe acute respiratory syndrome (SARS) is an infectious disease caused by a newly identified human coronavirus (SARS-CoV). Currently, no effective drug exists to treat SARS-CoV infection. In this study, we investigated whether a panel of commercially available antiviral drugs exhibit in vitro anti–SARS-CoV activity. A drug-screening assay that scores for virus-induced cytopathic effects on cultured cells was used. Tested were 19 clinically approved compounds from several major antiviral pharmacologic classes: nucleoside analogs, interferons, protease inhibitors, reverse transcriptase inhibitors, and neuraminidase inhibitors. Complete inhibition of cytopathic effects of SARS-CoV in culture was observed for interferon subtypes, β-1b, α-n1, α-n3, and human leukocyte interferon α. These findings support clinical testing of approved interferons for the treatment of SARS.
ncbi.nlm.nih.gov